Different vasculoprotective roles of NO synthase isoforms in vascular lesion formation in mice.
NO is known to have several important vasculoprotective actions. Although NO is synthesized by 3 different NO synthase (NOS) isoforms, the vasculoprotective action of individual NOS isoforms remains to be clarified. Permanent ligation of the left common carotid artery was performed in control, endothelial NOS (eNOS) knockout (eNOS-KO), and inducible NOS (iNOS) knockout (iNOS-KO) mice. Four weeks after the procedure, neointimal formation and reduction of cross-sectional vascular area (constrictive remodeling) were noted in the left carotid artery. In the eNOS-KO mice, the extent of neointimal formation was significantly larger than in the control or iNOS-KO mice, whereas the extent of vascular remodeling was the highest in the iNOS-KO mice compared with other 2 strains. Antiplatelet therapy with aspirin or antihypertensive treatment with bunazosin failed to inhibit the accelerated neointimal formation in the eNOS-KO mice. These results indicate that eNOS and iNOS have different vasculoprotective actions against the vascular lesion formation caused by blood flow disruption in vivo: NO derived from eNOS inhibits neointimal formation, whereas NO derived from iNOS suppresses the development of constrictive remodeling.
Yogo
K
K
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Shimokawa
H
H
Funakoshi
H
H
Kandabashi
T
T
Miyata
K
K
Okamoto
S
S
Egashira
K
K
Huang
P
P
Akaike
T
T
Takeshita
A
A
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D002339:Carotid Arteries / Q000201:enzymology* / Q000473:pathology*; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology; D007527:Isoenzymes / Q000097:blood / Q000235:genetics / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009389:Neovascularization, Pathologic / Q000201:enzymology* / Q000473:pathology / Q000517:prevention & control*; D019001:Nitric Oxide Synthase / Q000097:blood / Q000235:genetics / Q000502:physiology*; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D011799:Quinazolines / Q000494:pharmacology; D017539:Tunica Intima / Q000201:enzymology* / Q000473:pathology*
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D005343:Fibrinolytic Agents; D007527:Isoenzymes; D011799:Quinazolines; C018176:bunazosin; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; C496317:Nos2 protein, mouse; C496315:Nos3 protein, mouse; D001241:Aspirin